Aciphex, sold outside the US as Pariet, is a proton pump inhibitor licensed for erosive GERD, duodenal and gastric ulcer healing, H. pylori eradication triple therapy and Zollinger-Ellison syndrome, and FDA-approved generic rabeprazole tablets are available alongside the originator brand.
Aciphex, marketed outside the United States as Pariet and originated by Eisai, is an oral proton pump inhibitor built around a gastro-resistant tablet that pharmacists rely on for once-daily acid suppression across GERD, peptic ulcer and H. pylori regimens. M Care Exports is a merchant exporter: we source Aciphex/Pariet and FDA-approved generic rabeprazole tablets through licensed Indian distribution and manufacturing channels and dispatch on quote, not from our own manufacturing.
Rabeprazole exporter and bulk supplier from India.
For hospital, wholesaler and tender-desk orders, M Care quotes rabeprazole tablets against buyer specification: brand (Aciphex/Pariet) or generic, strength (10 mg or 20 mg, market-dependent) and destination-market regulatory documentation, drawn from licensed WHO-GMP manufacturer lines on the M Care roster. Because rabeprazole is frequently prescribed as part of a fixed antibiotic combination for H. pylori eradication, we confirm the buyer's intended regimen and pack configuration before dispatch, then align CTD/eCTD or country-specific dossier paperwork to the destination regulator's requirements.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Substituted benzimidazole proton pump inhibitor, sourced and documented for export.
Rabeprazole is a substituted benzimidazole proton pump inhibitor. It binds irreversibly to the H+/K+-ATPase enzyme on the gastric parietal cell, blocking the final step of acid secretion regardless of what stimulated it, which gives a longer duration of acid suppression than a single dose would suggest. It is dosed orally as a gastro-resistant (enteric-coated) tablet, swallowed whole and never chewed or crushed, since the coating protects the active drug from breakdown in stomach acid before it reaches the small intestine for absorption. Aciphex is FDA-labelled for the healing and symptomatic relief of erosive or ulcerative GERD, healing of duodenal ulcer, H. pylori eradication in combination with amoxicillin and clarithromycin, and long-term management of pathological hypersecretory conditions including Zollinger-Ellison syndrome, and the US product is marketed as a 20 mg tablet only. Pariet's UK/EU licence additionally covers active benign gastric ulcer and symptomatic GORD without oesophagitis at a lower 10 mg dose, so Pariet is available as both 10 mg and 20 mg gastro-resistant tablets. Destination-country labelling and strength availability should be checked against this before a tender quote is finalised. A US paediatric sprinkle-capsule formulation also exists in lower strengths but is a distinct dosage form, not part of the standard export tablet range.
Active ingredient
rabeprazole sodium. Substituted benzimidazole proton pump inhibitor.
Forms and strengths
10 mg gastro-resistant tablet; 20 mg gastro-resistant tablet.
Indications
Oral proton pump inhibitor indicated for erosive or ulcerative GERD, duodenal and gastric ulcer healing, H. pylori eradication in combination therapy and pathological hypersecretory conditions including Zollinger-Ellison syndrome, marketed as Aciphex (20 mg only) in the US and as Pariet (10 mg and 20 mg) elsewhere.
Administration
oral. Gastro-resistant (enteric-coated) tablet, swallowed whole, not chewed or crushed.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers for rabeprazole are mainly hospital and community gastroenterology pharmacies running acid-suppression and H. pylori eradication protocols, national and regional MoH tender desks maintaining a proton pump inhibitor formulary line, licensed pharmaceutical wholesalers and importers, and NGO or foundation procurement programmes supporting primary-care gastrointestinal treatment in markets where local registration is in place. Because rabeprazole competes with omeprazole, esomeprazole and pantoprazole for the same formulary slot, tender desks typically specify it where a shorter time-to-onset or a specific brand preference has been documented locally.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on rabeprazole.
Rabeprazole's enteric coating is the counselling point that matters most at dispensing: tablets must be swallowed whole, never split, chewed or crushed, since crushing exposes the active drug to gastric acid before it reaches the small intestine and destroys the intended release profile. For GERD healing, the FDA label runs 20 mg once daily for four to eight weeks, while the UK/EU SmPC adds a lower 10 mg once-daily option for symptomatic GORD without oesophagitis, so the strength ordered should match the licensed indication and destination market, not just the diagnosis. H. pylori eradication is a fixed seven-day combination, not a standalone prescription: 20 mg rabeprazole twice daily alongside amoxicillin 1 g twice daily and clarithromycin 500 mg twice daily, and a partial pack shipment breaks that regimen. Zollinger-Ellison syndrome dosing starts at 60 mg once daily and can be titrated well beyond the GERD range, up to 100 mg daily or a twice-daily split, so hypersecretory-condition orders should never be substituted against a standard GERD pack size. No dosage adjustment is required for renal or mild-to-moderate hepatic impairment, but severe hepatic impairment warrants caution and a lower starting dose per the SmPC.
The documentation pack a regulator actually asks for.
As an oral solid dosage form, rabeprazole travels on standard ambient-temperature logistics rather than the cold-chain lanes we validate for biologics and insulins; Aciphex is stored at 25°C with excursions permitted to 15-30°C, and Pariet's SmPC specifies storage below 25°C without refrigeration, so buyers should quote against whichever label applies to their destination market. What tender desks and importers need is batch-level certificate of analysis, CDSCO export documentation and, where the destination regulator requires it, CTD or eCTD-format dossier support so the buyer's own authority can register the product. Rabeprazole does not appear on the WHO Model List of Essential Medicines; omeprazole is the proton pump inhibitor WHO lists as the essential-medicines representative of the class, so rabeprazole functions as a formulary-specific or brand-preference alternative rather than an EML first-line agent, which buyers should factor into tender specification. On the brand-versus-generic question, Aciphex (US) and Pariet (most other markets) remain the originator products from Eisai, and FDA-approved generic rabeprazole sodium delayed-release tablets from multiple manufacturers, including Dr Reddy's, Lupin, Teva and Torrent, are separately registered, so buyers genuinely have a brand-or-generic choice; M Care quotes either against the tender specification and destination-market registration status. The MHRA issued a Class 4 medicines defect notification in January 2025 for a UK-marketed generic rabeprazole tablet over an outdated patient information leaflet, a reminder that batch-level documentation and current PIL/SmPC alignment matter as much as the underlying chemistry for a tender submission.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside rabeprazole.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for rabeprazole.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Rabeprazole supply, the specific questions.
Does a generic version of Aciphex/Pariet exist?
Yes. FDA-approved generic rabeprazole sodium delayed-release tablets are registered and marketed in the US alongside Eisai's Aciphex, from manufacturers including Dr Reddy's, Lupin, Teva and Torrent. Registration status for generic rabeprazole varies by destination country, so M Care checks local approval before quoting brand or generic against a specific tender.
Can M Care supply Aciphex or Pariet to our market?
Yes, on an import basis. We source Aciphex/Pariet through licensed Indian distribution channels and dispatch against your import authorisation and any local registration your pharmacy or hospital holds.
What strengths of rabeprazole tablets are available?
Pariet is licensed in the UK/EU as 10 mg and 20 mg gastro-resistant tablets; Aciphex in the US market is licensed only as a 20 mg tablet, with FDA-approved generics matching that strength. Tell us the indication (GERD, ulcer healing, H. pylori eradication or hypersecretory condition) and destination market, and we quote the matching strength and pack configuration.
Can rabeprazole tablets be crushed for patients who struggle to swallow?
No. Rabeprazole tablets are gastro-resistant and must be swallowed whole. Crushing or chewing destroys the enteric coating that protects the drug from stomach acid before it reaches the small intestine, and neither the FDA label nor the UK/EU SmPC supports an alternative administration route for this formulation.
How is rabeprazole dosed for H. pylori eradication?
As a fixed seven-day triple regimen: rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily and clarithromycin 500 mg twice daily, all with meals. Because it is a combination course, we quote and dispatch complete regimen packs rather than partial tablet counts.
Is rabeprazole on the WHO Essential Medicines List?
No. Omeprazole is the proton pump inhibitor WHO lists as the essential-medicines representative of the class. Rabeprazole is typically specified by tender desks as a formulary-specific or brand-preference alternative rather than a first-line EML agent.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-09-13.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.